Metabolically Healthy Obese

NCT ID: NCT06032312

Last Updated: 2023-09-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-12-01

Study Completion Date

2025-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Little is known about the associated factors and mechanisms involved in the development of metabolic disturbance in pediatric obesity. The overall objective of the present study is to investigate clinical, anthropometric, socio-demographic and lifestyle predictors of MHO among obese children and adolescents. The Aim of the present study is to investigate the effect of fat distribution, muscle mass, strength and physical activity level on metabolic morbidity in obese adolescents.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The global epidemic of childhood obesity and the accompanying rise in the prevalence of endocrine, metabolic, and cardiovascular comorbidities among the youth represents one of the most important public health issues of the modern world. The earlier occurrence and increase in the prevalence of both pediatric obesity and metabolic syndrome (MS) lead to a potential decline in life expectancy such that the youth of today could be the first generation to live shorter lives than their parents.

In the context of the childhood obesity pandemic, a distinct subgroup of obese youth who are less prone to the development of metabolic disturbances, termed "metabolically healthy obese" (MHO), has recently been characterized. Despite their obese state, MHO individuals display a "favorable" metabolic profile, with preserved insulin sensitivity, normal BP and glucose regulation, normal lipid and liver enzyme levels, as well as a normal hormonal, inflammation and immune profile. Although the MHO status might not necessarily translate into lower mortality and can evolve into "metabolically unhealthy obese" (MUO) phenotype during puberty, defining the MHO subpopulation among obese youth is critically important in order to elucidate the mechanisms protecting against the clustering of cardiometabolic risk factors, and their implications on clinical, preventive, and therapeutic decision-making.

Only few studies have evaluated predictors and risk factors for MUO, and they were based on a variety of definitions of MHO and the criteria used for defining it. Moreover, little is known about the mechanisms of the development of metabolic disturbances in pediatric obesity. More data are needed in order to identify the parameters most capable of predicting clinically significant outcomes. In this research, the researchers aim to investigate socio-demographic, clinical, anthropometric, physiological, and lifestyle predictors of MHO.

Aim:

1. To investigate socio-demographic, clinical, anthropometric, and lifestyle predictors for MHO.
2. To investigate the interaction between fat mass and distribution, muscle mass and strength and physical activity level on metabolic morbidity in obese adolescents.
3. To investigate the association between MHO predictors and metabolic disturbances.

Study design:

1\. Patient Population This prospective observational, cross-sectional study will be performed in the Nutrition and Obesity Clinic of the Pediatric Gastroenterology Unit at "Dana Dwek" Children's Hospital and at the "Gepner Lab" at the Sackler Faculty of Medicine.

Fifteen obese adolescents (age 12-18 years, body mass index \[BMI\] \>95th percentile) without metabolic risk factors and fifteen obese adolescents (matched for BMI z-score, sex and age) with 1 or more components of the metabolic syndrome will be recruited.

Exclusion criteria: Adolescents with background diseases or past/current treatment with medications that may influence body composition or metabolic risk (e.g., inflammatory conditions).

2 Data Collection

The information that will be obtained from the medical files will include:

1. Sociodemographic characteristics: sex, ethnicity, home address, number of children in the family, household (single parent/two parent), parents' level of education.
2. Medical history: perinatal characteristics (pregnancy, birth weight, gestational age, feeding practice during the first year of life), age of adiposity rebound, medications, menses (regular/irregular/oral contraceptives), sleep habits and family history of cardiometabolic diseases (diabetes, hypertension, dyslipidemia, cardiovascular disease, and cerebrovascular episodes) in first- and second-degree relatives.
3. The obese children's perceptions of their motivation, health and social status will be scored on a 1-10 scale and recorded at admission to the clinic.

All participants will undergo a clinical evaluation that includes a physical examination, systolic and diastolic BP and anthropometric measurements (height, weight, and calculated BMI).

CLINICAL AND METABOLIC ASSESSMENT Weight and height will be measured according to standardized protocols. BMI percentiles will be computed by means of sex- and age- specific BMI reference values from the Center for Disease Control and Prevention growth charts. Body composition will be assessed with bioelectrical impedance. Laboratory and radiologic parameters will include a liver enzyme profile, a lipid profile, glucose, insulin, HbA1c, and C-reactive protein levels, and abdominal ultrasonography. The participants will be referred for pelvic ultrasonography, polysomnography or an ophthalmologic evaluation if clinically indicated.

NUTRITIONAL ASSESSMENT The nutritional assessment will be based on an FFQ food report administered by a registered dietician at study entry.

BODY COMPOSITION ASSESSMENT

1. Lean body mass and fat mass will be calculated by bioelectrical impedance analysis by means of a multi-frequency SECA (mBCA 514 Medical) body composition analyzer. The participants will be required to wear light clothing during the body composition assessments and remove all jewelry, shoes, and socks. Measurements will be conducted in the morning following an overnight fast.
2. Abdominal adipose tissue distribution and liver fat will be assessed by MRI and MRS.

Muscle function and physical activity Muscle strength and function will be measured by a handgrip dynanometer. The participants will be asked to wear an accelerometer for 7 days in order to measure their levels of physical activity and sleep habits.
3. Definition of Study Variables Ethnicity will be defined as the birthplace of the parents or grandparents (if the parents were born in Israel) and categorized according to country of origin. Socioeconomic position will be determined by the patient's home address according to the Israel Central Bureau of Statistics' Characterization and Classification of Statistical Areas within Municipalities and Local Councils by the Socio-Economic Level of the Population 2015

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Metabolic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

metabolic healthy obese

description

Intervention Type OTHER

no intervention, just description of the groups

2

metabolic unhealthy obese

description

Intervention Type OTHER

no intervention, just description of the groups

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

description

no intervention, just description of the groups

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children aged 10-18 with obesity
* Attendance of the obesity clinic in the pediatric gastroenterology unit at "Dana-Dwek" children's hospital, Tel Aviv Sourasky Medical Center.

Exclusion Criteria

* Children with congenital or acquired heart disease
* Children with inflammatory conditions
* Children with neurological conditions that affect body composition
Minimum Eligible Age

10 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tel-Aviv Sourasky Medical Center

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Eli Sprecher, MD

Prof

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tel Aviv medical center

Tel Aviv, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hadar Moran Lev, MD

Role: CONTACT

972527360713

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hadar Moran Lev, MD

Role: primary

972527360713

References

Explore related publications, articles, or registry entries linked to this study.

Moran-Lev H, Sternfeld R, Lazmi R, Ohayon R, Dudi R, Brener A, Sagi SZ, Cohen S, Lubetzky R, Gepner Y. Hepatic fat and dietary intake as determinants of metabolic health in obese adolescents: a cross-sectional MRI study. Front Nutr. 2025 Jul 9;12:1559271. doi: 10.3389/fnut.2025.1559271. eCollection 2025.

Reference Type DERIVED
PMID: 40704318 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0799-20-TLV

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Gut Microbiome and Obesity
NCT04451148 UNKNOWN